熱門資訊> 正文
联合报告董事会重组后，Aurinia Pharmaceuticals股价上涨
2024-09-13 13:24
- Aurinia Pharmaceuticals (NASDAQ:AUPH) gained in extended trading on Thursday after the company said that it has restructured its Board of Directors.
- Peter Greenleaf, President and Chief Executive Officer of Aurinia (AUPH), remains a Director.
- Kevin Tang, President of Tang Capital Management, LLC, appointed as a Director.
- The Board has accepted the conditional resignations of three directors who received less than majority support at the 2024 Annual General Meeting.
- The restructured Board consists of seven members: Jeffrey A. Bailey; Robert T. Foster, Pharm.D., Ph.D., DSc; Peter Greenleaf; David R.W. Jayne, M.D., FRCP, FRCPE, FMedSci; Jill Leversage; Karen Smith, M.D., Ph.D., MBA, LLM; and Kevin Tang.
- Source: Press Release
More on Aurinia Pharma
- Aurinia Pharmaceuticals Appears Undervalued
- Aurinia Pharma Q2 2024 Earnings Preview
- Seeking Alpha’s Quant Rating on Aurinia Pharma
- Historical earnings data for Aurinia Pharma
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
